Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease

Authors

Sam Gandy, Thomas Jefferson University, Philadelphia
Ralph Martins, Edith Cowan University
Joseph Buxbaum, Mt. Sinai School of Medicine, New York

Document Type

Journal Article

Publisher

Lippincott Williams & Wilkins

Faculty

Faculty of Computing, Health and Science

School

School of Exercise, Biomedical and Health Science

RAS ID

2086

Comments

Gandy, S., Martins, R. N., & Buxbaum, J. (2003). Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 17(4), 259-266. Available here

Abstract

AIzheimer disease (AD) is characterized by clinical evidence of cognitive failure in association with cerebral amyloidosis, as well as cerebral intraneuronal neurofibrillary pathology, neuronal and synaptic loss, and neurotransmitter deficits. The cerebral amyloid of AD is deposited around meningeal and cerebral vessels, as well as in gray matter. In gray matter, the deposits are multifocal, coalescing into miliary structures known as plaques. Parenchymal amyloid plaques are distributed in brain in a characteristic fashion, differentially affecting the cerebrum and hippocampus, while largely sparing the basal ganglia, thalamus, spinal cord, and hindbrain.